MedTrace Logo

Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers

NCT00003754 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Thalidomide may kill tumor cells by stopping the growth of new blood vessels to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with chemotherapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and cyclophosphamide in treating children who have recurrent or refractory childhood cancers.

Conditions

  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG

thalidomide

DRUG

cyclophosphamide

Sponsors & Collaborators

Principal Investigators

  • Ira Dunkel, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-09-30
Primary Completion
2001-07-31
Completion
2001-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003754 on ClinicalTrials.gov